Chongqing Carelife Pharmaceutical is an API manufacturer based in China. It holds 24 active US drug master files across a filed portfolio of 21 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 28 March 2025 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3011903543 |
| Molecule | Regulators | Docs |
|---|---|---|
| Clindamycin | SFDA (Saudi Arabia), US FDA | 4 |
| Ferric Carboxymaltose | SFDA (Saudi Arabia), US FDA | 2 |
| Mitoxantrone | US FDA | 2 |
| Cabotegravir | US FDA | 1 |
| Canagliflozin | US FDA | 1 |
| Carfilzomib | US FDA | 1 |
| Dacomitinib | US FDA | 1 |
| Dolutegravir | US FDA | 1 |
| Entecavir | US FDA | 1 |
| Finerenone | US FDA | 1 |
| Glimepiride | US FDA | 1 |
| Granisetron | US FDA | 1 |
| Lenvatinib | US FDA | 1 |
| Nusinersen | US FDA | 1 |
| Palbociclib | US FDA | 1 |
| Pemetrexed | US FDA | 1 |
| Regorafenib | US FDA | 1 |
| Sorafenib | US FDA | 1 |
| Sucrose | US FDA | 1 |
| Tenofovir Alafenamide | US FDA | 1 |
| Venlafaxine | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 2 | None |
| US FDA | None | 1 |
Choose your molecules and target markets. Chongqing Carelife Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free